MedTrace Logo

Effect of Gutamine Administration in the Innate Immune System Response in ICU Patients.

NCT01250080 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2010-11-30

No results posted yet for this study

Summary

Glutamine is the most abundant nonessential amino acid in the human body. Besides its role as a constituent of proteins and its importance in amino acid transamination, glutamine may modulate immune cells.

The innate immune system is the first line of host defence against pathogens and in most cases sufficient to eliminate invading microbes. Mammalian Toll-like receptors (TLR) comprise a family of germ line-encoded trans-membrane receptors which activation leads to the induction of inflammatory responses, phagocytosis but also to the development of antigen specific adapative immunity.

It has been postulated though not formally proven yet that glutamine beneficial effect could be due to a positive effect on the innate immune system. Given the importance of TLRs and TLRs-dependent signalling in host defence against infections we hypothesized that glutamine may increase the expression and/or functionality of TLRs which in turn may have beneficial effects to clear infections.

Conditions

  • Moderate to Severe Trauma, as Defined by an
  • Injury Severity Score (ISS) > 12 Points Were Included in the Study.

Interventions

DIETARY_SUPPLEMENT

Total Parenteral Nutrition with Glutamine

daily glutamine supplement of 0.35 g/kg weight as N2-L-Alanyl-L-Glutamine (0.5 g/kg/d - Dipeptiven Fresenius Kabi España) during five days.

OTHER

Total Parenteral Nutrition without glutamine

The control group received a supplemental volume of the basic TPN solution to achieve an isocaloric an isonitrogenated formula with the study group.

Sponsors & Collaborators

  • Espen

    collaborator OTHER

  • This research prize was funded by Nestle Nutrition Institute and by Fresenius Kabi.

    collaborator UNKNOWN

  • Hospital Universitari Son Dureta

    lead OTHER

Study Design

Allocation
RANDOMIZED
Masking
SINGLE

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2008-06-30
Completion
2008-09-30

Countries

  • Spain

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01250080 on ClinicalTrials.gov